Prostate cancer foundation hormone-sensitive Prostate Cancer Biomarker Working Group meeting summary Editorial

  


Authors: Hofmann, M. R.; Hussain, M.; Dehm, S. M.; Beltran, H.; Wyatt, A. W.; Halabi, S.; Sweeney, C.; Scher, H. I.; Ryan, C. J.; Feng, F. Y.; Attard, G.; Klein, E.; Miyahira, A. K.; Soule, H. R.; Sharifi, N.
Title: Prostate cancer foundation hormone-sensitive Prostate Cancer Biomarker Working Group meeting summary
Abstract: Androgen deprivation therapy remains the backbone therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, several treatments, including docetaxel, abiraterone + prednisone, enzalutamide, and apalutamide, have each been shown to demonstrate survival benefit when used upfront along with androgen deprivation therapy. However, treatment selection for an individual patient remains a challenge. There is no high level clinical evidence for treatment selection among these choices based on biological drivers of clinical disease. In August 2020, the Prostate Cancer Foundation convened a working group to meet and discuss biomarkers for hormone-sensitive prostate cancer, the proceedings of which are summarized here. This meeting covered the state of clinical and biological evidence for systemic therapies in the mHSPC space, with emphasis on charting a course for the generation, interrogation, and clinical implementation of biomarkers for treatment selection. © 2020 The Author(s)
Keywords: unclassified drug; oncoprotein; review; protein p53; tumor marker; cancer research; cancer therapy; prostate cancer; oncogene; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; androgen receptor; nomenclature; metastasis potential; antiandrogen; retinoblastoma protein; hormone sensitivity; clinical trial (topic); human; circulating tumor dna; spop protein; hsd3b1 gene
Journal Title: Urology
Volume: 155
ISSN: 0090-4295
Publisher: Elsevier Science, Inc.  
Date Published: 2021-09-01
Start Page: 165
End Page: 171
Language: English
DOI: 10.1016/j.urology.2020.12.021
PUBMED: 33373705
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099457596&doi=10.1016%2fj.urology.2020.12.021&partnerID=40&md5=6ca373085384d18ad7c3fb9f135b0bb5
Notes: Review -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Howard Scher
    1130 Scher
Related MSK Work